TheLiverDoc Gets Breathing Room: Kerala HC Pauses Defamation Summons Over Herbal Medicine Tweet

In a swift move balancing free speech and reputation, the Kerala High Court has granted interim relief to prominent hepatologist Dr. Cyriac Abby Philips, known online as TheLiverDoc . On April 28, 2026 , Justice Jobin Sebastian admitted Dr. Philips' criminal miscellaneous petition (Crl.MC No. 3647 of 2026) challenging a defamation summons and deferred his required appearance in the lower court until the next hearing on May 22, 2026 .

The single-judge bench issued notice to the Ayurvedic firm SNA Oushadhasala Pvt Ltd, the complainant, signaling deeper scrutiny ahead.

From Twitter Warning to Court Battle

Dr. Philips, a senior consultant in clinical and translational hepatology at Rajagiri Hospital in Aluva, is a vocal advocate for evidence-based medicine. With a massive following on X (formerly Twitter), he frequently critiques unverified claims in alternative therapies.

Trouble brewed in March 2024 when he posted about a patient suffering acute liver failure—allegedly linked to a traditional Ayurvedic medicine—and placed on ventilator support. The post labeled Ayurveda a "pseudoscience," included images of products from SNA Oushadhasala Pvt Ltd, and warned of herb-induced liver injury (HILI) backed by medical records, tests, and biopsy.

The Thrissur-based firm, represented by its managing director Dr. PTN Vasudevan Moosa, filed a private complaint (CC 120/2025) before the Chief Judicial Magistrate Court, Thrissur . Invoking Sections 499 and 500 IPC (defamation and punishment for it), they argued the post falsely implicated their products, tarnishing their goodwill.

The magistrate took cognizance , rejecting Dr. Philips' claim to exceptions under Section 499 IPC —like good faith for public good —and issued summons. Dr. Philips then approached the High Court under inherent powers (likely Section 482 CrPC ) to quash the proceedings .

Petitioner's Defense: Science Over Silence

Dr. Philips, through a battery of counsel including senior advocates, contended the post was a professional duty to alert the public on HILI risks from unregulated herbals. He stressed it drew from a real patient's case, didn't name the firm explicitly, and fell under Section 499 exceptions for statements made in good faith for the public's benefit.

The plea framed the case as an attempt to muzzle scientific dissent and public health discourse, urging the court to nip abuse of process at the summons stage.

Complainant's Grievance: Reputation Under Fire

SNA Oushadhasala claimed the post, with product images, created a direct impression of causation—liver damage from their medicines—eroding public trust. They argued exceptions to defamation are trial matters, not pre-emptive shields.

The state, via public prosecutor, took notice but the firm awaits formal response post-notice.

Court's Calculated Pause

Justice Sebastian, after hearing Dr. Philips' senior counsel, found prima facie merit . The order states: "Having considered the submissions made by the learned counsel and the averments contained in the petition, the appearance of the accused pursuant to the summons issued by the Jurisdictional Court shall stand deferred till the next posting of this Crl.MC."

No precedents were cited in this interim order, but the deference hints at upcoming analysis of Section 499 defenses and quashing thresholds under CrPC.

Key Observations from the Bench

  • "Admit." – Straight admission signals the petition's viability.
  • "Issue notice to the 2nd respondent." – Ensuring all sides heard.
  • "Heard the learned Senior counsel who appeared for the petitioner." – Acknowledging substantive arguments at threshold.

What Next for Docs, Tweets, and Tonics?

This stay halts immediate compliance, buying time for full arguments. If quashed, it could embolden clinicians critiquing alternatives amid rising HILI cases. For SNA and peers, a reminder: social media scrutiny cuts both ways, but courts guard against hasty process.

Post on May 22, 2026 , could reshape when online medical warnings cross into defamation territory—vital for India's heated alt-med debates.